Gallen consensus on early-stage breast cancer recommends making clinical treatment decisions based on the surrogates of molecular subtypes (luminal-A, luminal-B, HER2-positive, and basal-like) defined by ER, PgR, HER2, and Ki67 [11]. The gene discussed is ERBB2; the disease is breast carcinoma.